Business Description
Guard Therapeutics International AB
ISIN : SE0021181559
Total Employee Number:
5Compare
Compare
Traded in other countries / regions
GUARD.Sweden5LH0.Germany IPO Date
2013-04-03Description
Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.81 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 26.7 | |||||
3-Year EPS without NRI Growth Rate | 26.7 | |||||
3-Year FCF Growth Rate | 24.2 | |||||
3-Year Book Growth Rate | -50.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.61 | |||||
9-Day RSI | 52.03 | |||||
14-Day RSI | 52.49 | |||||
3-1 Month Momentum % | 23.26 | |||||
6-1 Month Momentum % | -11.67 | |||||
12-1 Month Momentum % | -91.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.13 | |||||
Quick Ratio | 7.13 | |||||
Cash Ratio | 6.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.3 | |||||
Shareholder Yield % | -381.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -149.72 | |||||
ROA % | -117.74 | |||||
ROIC % | -499.94 | |||||
3-Year ROIIC % | -135.6 | |||||
ROC (Joel Greenblatt) % | -208 | |||||
ROCE % | -145.35 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.68 | |||||
PB Ratio | 0.87 | |||||
Price-to-Tangible-Book | 0.87 | |||||
EV-to-EBIT | 0.12 | |||||
EV-to-Forward-EBIT | 0.2 | |||||
EV-to-EBITDA | 0.12 | |||||
EV-to-Forward-EBITDA | 0.2 | |||||
EV-to-Forward-Revenue | 0.16 | |||||
EV-to-FCF | 0.12 | |||||
| Price-to-Net-Current-Asset-Value | 0.87 | |||||
| Price-to-Net-Cash | 0.98 | |||||
Earnings Yield (Greenblatt) % | 866.32 | |||||
FCF Yield % | -258.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guard Therapeutics International AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -4.075 | ||
| Beta | -0.0975 | ||
| 3-Year Sharpe Ratio | 0.46 | ||
| 3-Year Sortino Ratio | 1.52 | ||
| Volatility % | 115.23 | ||
| 14-Day RSI | 52.49 | ||
| 14-Day ATR (kr) | 0.161566 | ||
| 20-Day SMA (kr) | 1.5734 | ||
| 12-1 Month Momentum % | -91.45 | ||
| 52-Week Range (kr) | 0.881 - 27 | ||
| Shares Outstanding (Mil) | 20.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guard Therapeutics International AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guard Therapeutics International AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 37 days | ||
| General meeting for 2026 | 2026-05-18 | 1.45 (+12.25%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 1.19 (+11.65%) | ||
| Annual report for 2025 | 2026-04-21 | 1.18 (-3.12%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-20 | 1.60 (+0.63%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 1.52 (+8.57%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 23.40 (-0.43%) | ||
| General meeting for 2025 | 2025-05-15 10:00 | 15.10 (+10.22%) | ||
| First quarter earnings results for 2025 | 2025-05-05 | 13.75 (+3.00%) |
Show
Entries
Guard Therapeutics International AB Frequently Asked Questions
What is Guard Therapeutics International AB(OSTO:GUARD)'s stock price today?
The current price of OSTO:GUARD is kr1.58. The 52 week high of OSTO:GUARD is kr27.00 and 52 week low is kr0.88.
When is next earnings date of Guard Therapeutics International AB(OSTO:GUARD)?
The next earnings date of Guard Therapeutics International AB(OSTO:GUARD) is 2026-08-20.
Does Guard Therapeutics International AB(OSTO:GUARD) pay dividends? If so, how much?
Guard Therapeutics International AB(OSTO:GUARD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Guard Therapeutics International AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers